Merck gains EU approval for Keytruda plus Padcev in bladder cancer
Merck (NYSE:MRK) announced that the European Commission approved KEYTRUDA (pembrolizumab), in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment followed by adjuvant treatment after radical cystectomy for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.




_1427264_640x360_2504590403574-640x360.webp&w=3840&q=75)

-640x360.webp&w=3840&q=75)
_1427245_640x360_2504589379776-640x360.webp&w=3840&q=75)


_1427222_640x360_2504591939673-640x360.webp&w=3840&q=75)
_1427207_640x360_2504587331968-640x360.webp&w=3840&q=75)